A Chinese Foreign Ministry spokesman on Thursday urged relevant countries to immediately halt military operations, as the situation in the Middle East is disrupting global energy security.
Lin Jian, the spokesman, made the remark during a regular press briefing in Beijing in response to a media inquiry on the Philippines and energy security.
"The situation in the Middle East dealt a heavy blow to global energy security. Relevant countries should immediately stop military operations and prevent regional turmoil from further impacting global economic development. China stands ready to strengthen coordination and collaboration with Southeast Asian countries to jointly address the issues of energy security," said Lin.
The conflict, which began with attacks by the United States and Israel against Iran, has spread beyond direct clashes to involve multiple Gulf states. This escalation is heightening regional instability and raising tensions over the Strait of Hormuz, a vital shipping route for oil and gas.
China urges halt to military operations as Middle East crisis threatens global energy security
China's Minister of Commerce Wang Wentao met with global pharmaceutical leaders in Beijing for a high-level dialogue.
The meeting brought together policymakers and senior executives from multinational drugmakers including Novartis, AstraZeneca, Roche, Boehringer Ingelheim and Organon.
"The pharmaceutical industry is vital to human health, we welcome your views and suggestions on development in China,” Wang said while addressing participants at the high-level dialogue.
Drawing growing global attention, China is now one of the world’s fastest-evolving markets and is signaling openness by inviting deeper engagement from multinational companies already investing in the country, according to U.S. pharmaceutical officials.
"For the innovative pharmaceutical sector, China has become one of the world's largest and fastest evolving markets, playing an increasingly global role," said Stephen J. Ubl, president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA).
From cutting-edge biotech to large-scale manufacturing, global firms say China’s appeal lies in its unique combination of scale and capabilities.
"Key factors in this evolution include China's large patient population, scientific talent, clinical research capacity, and investments in science and healthcare," said Ubl.
China’s commerce minister meets global pharma leaders
